Fundz

Q32 Bio Appoints Saul Fink, Ph.D. as Chief Technology Officer

PUBLIC · QTTBOct 24, 2023

Position

Chief Technical Officer

Company

Q32 Bio

Saul Fink
sfink@q32bio.com
WalthamBiotechnologyHealthcareHealth CareTherapeutics

Description

Q32 Bio, a clinical stage biotechnology company developing biologic therapeutics to restore immune homeostasis, today announced the appointment of Saul Fink, Ph.D., as Chief Technology Officer. Dr. Fink will be responsible for all aspects of Q32 Bio's chemistry, manufacturing and control -related activities.

Other recent leadership changes in Healthcare and Therapeutics

Executive moves at companies in the same sectors within 45 days, from Fundz verified event records.

Who to call at Q32 Bio, and when

A new leader at Q32 Bio brings new priorities and often new vendors. The first weeks are when they listen.

  • An alert the day Q32 Bio raises, hires an executive or expands, scored against what you sell
  • The decision-makers there, with verified emails
  • Who you already know at Q32 Bio, from your own LinkedIn network

Works inside ChatGPT and Claude. Ask who to call at Q32 Bio. With Fundz connected, it knows.

Watch Fundz in
See plan options
Trusted byOracleSnowflakeCloudflareLinkedInGoogleSalesforce 4.8/5 on G2

Company Information

Company

Q32 Bio

Location

Waltham, Massachusetts, United States

About

Q32 Bio is a clinical stage biotechnology company whose science targets potent regulators of the adaptive immune system to re-balance immunity and is focused on developing innovative therapies for alopecia areata and other autoimmune and inflammatory diseases. Per the National Alopecia Areata Foundation, about 700,000 people in the United States live with alopecia areata, a disease which has a life-altering impact on patients and limited current treatment options. The Company is advancing bempikibart (ADX-914), a fully human anti-IL-7Rα antibody that re-regulates adaptive immune function, for the treatment of alopecia areata in an ongoing Phase 2 program. The IL-7 and TSLP pathways have been genetically and biologically implicated in driving several T cell-mediated pathological processes in numerous autoimmune diseases.

AI made execution free. Knowing first is the whole game now.

Fundz sees it the moment Q32 Bio changes its leadership, hires an exec or expands, usually minutes after it happens, and tells you who to reach.

Related People

Joel
Senior decision-maker at this company
••••••••@••••••••

See Joel's verified email →

Create an account to reveal verified emails
Predictive Intelligence
Strategic

ML-powered predictions for Q32 Bio's next move

Learn about Strategic plan

Q32 Bio changed its leadership. Fundz had it the day it was filed, with the decision-maker at the company attached.

145 of these a day, filtered to the companies you pick, with the decision-maker attached.

5 screens from a live account. No signup.

Fundz is a real-time business intelligence platform powered by agentic AI that proactively delivers personalized daily signals, including funding rounds, executive changes, M&A activity, 13F institutional filings, SEC 8-K events, investor activity, and website modifications, based on each user's watchlist and ICP. A trusted data source at firms such as BlackRock, Oracle, Kleiner Perkins, LinkedIn, HubSpot, and Cloudflare, Fundz democratizes the institutional-grade intelligence that previously required a PitchBook or Bloomberg terminal. Features include Daily Briefing for AI-powered daily briefings, and unified cross-signal alerts across 281,000+ organizations. Developers and data teams can access these signals programmatically via the Fundz Funding Data API, with transparent published pricing.